Treatment FailureHeart FailureTreatment OutcomeAntimalarialsDrug CombinationsSulfadoxinePyrimethamineDrug ResistanceRetrospective StudiesDrug Therapy, CombinationFollow-Up StudiesProspective StudiesMalaria, FalciparumAnti-Bacterial AgentsTime FactorsRecurrenceChloroquineArtemisininsSeverity of Illness IndexRisk FactorsPrognosisAmodiaquineKidney Failure, ChronicFluorenesProguanilFailure to ThriveSurvival AnalysisPlasmodium falciparumCohort StudiesDrug Administration ScheduleAtovaquoneDihydropteroate SynthaseHIV InfectionsCefiximeDrug Resistance, ViralAnti-HIV AgentsDepressionSymptom AssessmentAntiprotozoal AgentsLiver Failure, AcutePredictive Value of TestsAntitubercular AgentsMicrobial Sensitivity TestsAmoxicillinAntineoplastic Combined Chemotherapy ProtocolsQuestionnairesAcute DiseaseSurvival RatePenicillin G ProcaineCombined Modality TherapyParasitic Sensitivity TestsMetronidazoleChronic DiseaseDisease-Free SurvivalGonorrheaPrevalenceDisease ProgressionViral LoadDrug Resistance, BacterialDrug MonitoringLiver FailureAzithromycinQuality of LifeMelarsoprolKaplan-Meier EstimateFluoxymesteroneEthanolaminesGenotypeParasitemiaMultiple Organ FailureAntiretroviral Therapy, Highly ActiveUgandaHodgkin DiseaseMutationSalvage TherapyPatient ComplianceAnti-Infective AgentsDoxorubicinVincristineCeftriaxoneMycoplasma genitaliumPsychiatric Status Rating ScalesPharyngeal DiseasesBehavioral SymptomsTrypanosoma brucei gambienseMultivariate AnalysisClinical Trials as TopicDouble-Blind MethodCD4 Lymphocyte CountPrednisoneAge FactorsTetrahydrofolate DehydrogenaseEquipment FailureAdministration, OralCardiac Output, LowPolymerase Chain ReactionAntimonyRandomized Controlled Trials as TopicCross-Sectional StudiesRisk Assessment